Drive strategic execution across a complex territory or multi-state geography, delivering sustained commercial impact.
Expand relationships with healthcare providers and build relations with influential stakeholders to further the knowledge of Exelixis oncology therapies and ensure appropriate use.
Leverage advanced analytics and market insights to refine territory strategy and influence internal planning.
Partner cross-functionally to deliver coordinated solutions that address clinical, operational, and access challenges.
Represent field perspectives in brand planning discussions and contribute to tactical innovation.
Identify emerging trends, competitive threats, and unmet needs within the territory.
Model excellence in compliance, professionalism, and ethical engagement.
Lead strategic pull-through initiatives in collaboration with access and reimbursement teams.
Serve as a field-based ambassador for new product launches, pilots, and strategic initiatives.
Cultivate relationships with key opinion leaders, integrated delivery networks, and institutional decision-makers.
Support regional leadership in business planning, training, and performance calibration.
Serve as a mentor and resource to junior team members, sharing best practices and supporting skill development.
Requirements
BS/BA degree in related discipline and 9 years of related experience; or Master’s degree in related discipline and 7 years of related experience; or Equivalent combination of education and experience
Minimum of 5 years of oncology sales experience
Launch experience required
Ability to persuade by presenting complex clinical information
Strong business planning a requirement
Ability to work independently
Benefits
401k plan with generous company contributions
Group medical, dental and vision coverage
Life and disability insurance
Flexible spending accounts
Discretionary annual bonus program or sales-based incentive plan
Opportunity to purchase company stock
Long-term incentives
15 accrued vacation days in the first year
17 paid holidays including a company-wide winter shutdown in December